GlassScriptPhysician profile
Karen Barker
NPI 1629268263
$19,090.48
in general payments reported to CMS, 2019-2025
44 companies · $4,241 in 2025
The $4,241 reported for 2025 was more than what 82% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,308 · 2020: $1,450 · 2021: $2,753 · 2022: $2,805 · 2023: $3,071 · 2024: $3,462 · 2025: $4,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $73.50 · Consulting Fee: $19.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,681.51 |
| Education | $73.50 |
| Consulting Fee | $19.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,282.92 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $2,276.28 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $1,832.76 | 2020-2025 | Cuvitru, Hyqvia, Takhzyro |
| Genzyme Corporation | $1,710.24 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,504.94 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $1,103.88 | 2019-2025 | Xolair |
| Csl Behring | $1,033.31 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Pfizer INC. | $774.32 | 2019-2025 | |
| Optinose US, INC. | $624.69 | 2019-2025 | |
| Amgen INC. | $483.06 | 2021-2025 | Tezspire, Actimmune |
| Kaleo, INC. | $442.25 | 2019-2024 | Auvi-Q |
| Grifols USA, LLC | $431.07 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $350.39 | 2020-2025 | Spiriva Respimat, Ofev, Stiolto Respimat |
| Novartis Pharmaceuticals Corporation | $301.31 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $221.15 | 2021-2025 | Orladeyo |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $213.88 | 2021-2025 | Opzelura |
| Abbvie INC. | $205.18 | 2022-2023 | Rinvoq |
| Lilly USA, LLC | $200.10 | 2024-2025 | Ebglyss |
| Viatris Specialty LLC | $188.44 | 2025 | Yupelri |
| Pharming Healthcare, INC. | $176.01 | 2019-2025 | Ruconest |
| Mylan Specialty L.P. | $157.28 | 2020-2024 | Yupelri |
| Blueprint Medicines Corporation | $152.57 | 2023-2024 | Ayvakit |
| Shire North American Group INC | $150.87 | 2019 | |
| Organon LLC | $143.20 | 2025 | Vtama |
| Ars Pharmaceuticals Operations, INC. | $136.82 | 2025 | Neffy |
| Philips North America LLC | $123.44 | 2021-2025 | Vest Therapy Und |
| Sanofi-Aventis U.S. LLC | $88.18 | 2019-2021 | |
| Leo Pharma INC. | $71.66 | 2022-2023 | Adbry |
| Aytu Biopharma, INC. | $71.20 | 2024-2025 | Karbinal |
| Insmed, INC. | $70.61 | 2025 | Arikayce, Brinsupri |
| Phadia US INC. | $69.11 | 2022-2024 | Immunocap |
| Verona Pharma, INC. | $66.34 | 2025 | Ohtuvayre |
| Alk-Abello, INC | $63.07 | 2020-2022 | |
| Electromed, INC. | $46.26 | 2025 | Smartvest |
| Glaukos Corporation | $44.14 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $41.60 | 2021 | |
| Ionis Pharmaceuticals, INC. | $40.07 | 2025 | Dawnzera |
| Merck Sharp & Dohme LLC | $39.90 | 2021 | |
| Pulmonx Corporation | $38.34 | 2022-2023 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Hikma Pharmaceuticals USA | $29.23 | 2023-2024 | Ryaltris |
| Sunovion Pharmaceuticals INC. | $29.15 | 2019 | |
| Aimmune Therapeutics, INC. | $25.25 | 2022 | |
| Adma Biomanufacturing LLC | $19.88 | 2023 | |
| Axsome Therapeutics, INC. | $16.13 | 2025 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Barker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.